Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer

BMC Research Notes

Lee S Schwartzberg²  Edward J Stepanski¹  Yeun Mi Yim³  Jiandong Kerr¹  Elaine Yu Pharm³  Mark S Walker⁴ 

[1] ACORN Research, LLC, Memphis, TN, USA;The West Clinic, Memphis, TN, USA;Genentech, South San Francisco, CA, USA;6555 Quince, Suite 400, Memphis, TN, 38119, USA

关键词: Dermatologic symptoms;    Health outcomes;    Chemotherapy;    Cetuximab;    Bevacizumab;   

Others  :  1166251
DOI  :  10.1186/1756-0500-5-314

 received in 2012-05-29, accepted in 2012-06-06,  发布年份 2012

【 摘 要 】

Background

Bevacizumab (B) and cetuximab (C) are both approved for use in the treatment of metastatic colorectal cancer (mCRC) in the second-line. We examined patient reported symptom burden during second-line treatment of mCRC.

Methods

Adult mCRC patients treated in the second-line setting with a regimen that included B, C, or chemotherapy only (O) and who had completed ≥ 1 Patient Care Monitor (PCM) surveys as part of routine clinical care were drawn from the ACORN Data Warehouse. Primary endpoints were rash, dry skin, itching, nail changes, nausea, vomiting, fatigue, burning in hands/feet, and diarrhea. Linear mixed models examined change in PCM scores across B, C and O (B = reference).

Results

182 patients were enrolled (B: n = 106, C: n = 38, O: n = 38). Patients were 51% female, 67% Caucasian, with mean age of 62.0 (SD = 12.6). Groups did not differ on demographic or clinical characteristics. The most common second-line regimens were FOLFIRI ± B or C (23.1%) and FOLFOX ± B or C (22.5%). Results showed baseline scores to be strongly predictive of second-line symptoms across all PCM items (all p’s < .0001 except for Rash, p = .0013). Controlling for baseline, patients on B tended to have more stable and less severe symptoms. Patients on C had more severe rash, dry skin, and itching and had nail change scores that worsened faster than did B patients.

Conclusions

Patients receiving second-line treatment for mCRC with B report less symptom burden, especially dermatologic, compared to patients treated with C.

【 授权许可】

   
2012 Walker et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]American Cancer Society: Colorectal Cancer Facts & Figures 2011–2013 Atlanta. American Cancer Society, GA; 2011.
• [2]Coutinho AK, Rocha Lima CM: Metastatic colorectal cancer: systemic treatment in the new millennium. Cancer Control 2003, 10(3):224-238.
• [3]Rougier P, Mitry E: Epidemiology, treatment and chemoprevention in colorectal cancer. Ann Oncol 2003, 14(Suppl 2)):ii3-ii5.
• [4]Starling N, Tilden D, White J, Cunningham D: Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer 2007, 96(2):206-212.
• [5]Capdevila J, Ramos FJ, Macarulla T, Elez E, Tabernero J: The role of salvage treatment in advanced colorectal cancer. Crit Rev Oncol Hematol 2009, 71(1):53-61.
• [6]Kelly H, Goldberg RM: Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005, 23(20):4553-4560.
• [7]The National Comprehensive Cancer Network: Clinical practice guidelines in oncology: colon cancer, version 3.2011. The National Comprehensive Cancer Network 2011.
• [8]The National Comprehensive Cancer Network: Clinical practice guidelines in oncology: rectal cancer, version 4.2011. The National Comprehensive Cancer Network 2011.
• [9]ImClone and Bristol-Myers Squibb: Erbitux drug label. ImClone and Bristol-Myers Squibb 2010.
• [10]Genentech: Drug label for Avastin. Genentech 2009.
• [11]Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T, Schoffski P, et al.: Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? Eur J Cancer 2006, 42(1):42-49.
• [12]Efficace F, Innominato PF, Bjarnason G, Coens C, Humblet Y, Tumolo S, et al.: Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2008, 26(12):2020-2026.
• [13]Maisey NR, Norman A, Watson M, Allen MJ, Hill ME, Cunningham D: Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer 2002, 38(10):1351-1357.
• [14]Feyer P, Kleeberg UR, Steingraber M, Gunther W, Behrens M: Frequency of side effects in outpatient cancer care and their influence on patient satisfaction–a prospective survey using the PASQOC questionnaire. Support Care Cancer 2008, 16(6):567-575.
• [15]Gupta D, Lis CG, Grutsch JF: The relationship between cancer-related fatigue and patient satisfaction with quality of life in cancer. J Pain Symptom Manage 2007, 34(1):40-47.
• [16]Lis CG, Gupta D, Grutsch JF: The relationship between insomnia and patient satisfaction with quality of life in cancer. Support Care Cancer 2008, 16(3):261-266.
• [17]Osoba D, Hsu MA, Copley-Merriman C, Coombs J, Johnson FR, Hauber B, et al.: Stated preferences of patients with cancer for health-related quality-of-life (HRQOL) domains during treatment. Qual Life Res 2006, 15(2):273-283.
• [18]Mittmann N, Seung SJ: Rash rates with EGFR inhibitors: meta-analysis. Curr Oncol 2011, 18(2):e54-e63.
• [19]Ouwerkerk J, Boers-Doets C: Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Eur J Oncol Nurs 2010, 14(4):337-349.
• [20]Fortner BV, Schwartzberg LS, Stepanski EJ, Houts AC: Symptom burden for patients with metastatic colorectal cancer treated with first-line FOLFOX or FOLFIRI with and without bevacizumab in the community setting. Supportive Cancer Therapy 2007, 4(4):233-240.
• [21]Conroy T, Hebbar M, Bennouna J, Ducreux M, Ychou M, Lledo G, et al.: Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer. Br J Cancer 2010, 102(1):59-67.
• [22]Funaioli C, Longobardi C, Martoni AA: The impact of chemotherapy on overall survival and quality of life of patients with metastatic colorectal cancer: a review of phase III trials. J Chemother 2008, 20(1):14-27.
• [23]Fortner B, Okon T, Schwartzberg L, Tauer K, Houts AC: The Cancer Care Monitor: psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients. J Pain Symptom Manage 2003, 26(6):1077-1092.
• [24]Fortner B, Baldwin S, Schwartzberg L, Houts AC: Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation. J Pain Symptom Manage 2006, 31(3):207-214.
• [25]Houts AC, Lipinski D, Olsen JP, Baldwin S, Hasan M: Use of the Patient Care Monitor to screen for depression in adult cancer patients interviewed with the structured clinical interview for DSM-IV. Psychooncology 2010, 19(4):399-407.
• [26]Walker MS, Schwartzberg LS, Stepanski EJ, Fortner BV: A retrospective study of quality of life in a community sample of patients with early stage breast cancer. Breast Cancer Res Treat 2009, 115(2):415-422.
• [27]Stepanski EJ, Walker MS, Schwartzberg LS, Blakely LJ, Ong J, Houts AC: The relation of trouble sleeping, depressed mood, pain and fatigue in patients with cancer. J Clin Sleep Med 2009, 5(2):132-136.
• [28]Littell RC, Pendergast J, Natarajan R: Modelling covariance structure in the analysis of repeated measures data. Stat Med 2000, 19(13):1793-1819.
• [29]Cnaan A, Laird NM, Slasor P: Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med 1997, 16(20):2349-2380.
• [30]Houts A, Lalla D, Walker M, Stepanski E, Brammer M, Doan J, et al.: Symptom burden declines when breast cancer patients treated with adjuvant trastuzumab/combination chemotherapy regimens enter trastuzumab monotherapy follow-up. San Antonio Breast Cancer Symposium; 2010 December 8–12; San Antonio, TX 2010.
• [31]Walker MS, Stepanski EJ, Reyes C, Satram-Hoang S, Houts AC, Schwartzberg LS: Symptom burden and quality of life in patients with follicular lymphoma undergoing maintenance treatment with rituximab compared with observation. Ther Adv Hematol 2011, 2(3):129-139.